Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > ARD003 article

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Sep 29, 2021 8:42am

146 Views

Post# 33935858

RE:ARD003 article

Interesting part for this trial is bigger that what I thought. It is kinda of international in 4 countries and the products are already ready to inject ppl. So once sites confirmed work will.

latest article published in Canadian biotechnology about tetra ard003. Guys this is only one of many

https://issuu.com/biotecanada_insights/docs/btc_insights_fall_2021[/quote]

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market